Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2013 4
2015 1
2016 3
2018 1
2019 2
2020 1
2021 5
2022 7
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Cannabinoids and Chronic Liver Diseases.
Mboumba Bouassa RS, Sebastiani G, Di Marzo V, Jenabian MA, Costiniuk CT. Mboumba Bouassa RS, et al. Int J Mol Sci. 2022 Aug 20;23(16):9423. doi: 10.3390/ijms23169423. Int J Mol Sci. 2022. PMID: 36012687 Free PMC article. Review.
Effects of Oral Cannabinoids on Systemic Inflammation and Viral Reservoir Markers in People with HIV on Antiretroviral Therapy: Results of the CTN PT028 Pilot Clinical Trial.
Mboumba Bouassa RS, Comeau E, Alexandrova Y, Pagliuzza A, Yero A, Samarani S, Needham J, Singer J, Lee T, Bobeuf F, Vertzagias C, Sebastiani G, Margolese S, Mandarino E, Klein MB, Lebouché B, Routy JP, Chomont N, Costiniuk CT, Jenabian MA. Mboumba Bouassa RS, et al. Cells. 2023 Jul 8;12(14):1811. doi: 10.3390/cells12141811. Cells. 2023. PMID: 37508476 Free PMC article.
To assess the effects of oral cannabinoids during HIV, ten PWH on ART were randomized (n = 5/group) to increasing doses of oral delta9-tetrahydrocannabinol (THC): cannabidiol (CBD) combination (2.5:2.5-15:15 mg/day) capsules or CBD-only (200-800 mg/day) capsules for 12 wee …
To assess the effects of oral cannabinoids during HIV, ten PWH on ART were randomized (n = 5/group) to increasing doses of oral delta …
FoxP3+ CD8 T-cells in acute HIV infection and following early antiretroviral therapy initiation.
Yero A, Shi T, Routy JP, Tremblay C, Durand M, Costiniuk CT, Jenabian MA. Yero A, et al. Front Immunol. 2022 Jul 29;13:962912. doi: 10.3389/fimmu.2022.962912. eCollection 2022. Front Immunol. 2022. PMID: 35967314 Free PMC article.
METHODS: Subsets of FoxP3(+) CD8 T-cells were characterized both prospectively and cross-sectionally in PBMCs from untreated acute (n=26) and chronic (n=10) HIV-infected individuals, early ART-treated in acute infection (n=10, median of ART initiation: 5.5 mo …
METHODS: Subsets of FoxP3(+) CD8 T-cells were characterized both prospectively and cross-sectionally in PBMCs from untreated acute (n …
Association Between the Development of Subclinical Cardiovascular Disease and Human Immunodeficiency Virus (HIV) Reservoir Markers in People With HIV on Suppressive Antiretroviral Therapy.
Turcotte I, El-Far M, Sadouni M, Chartrand-Lefebvre C, Filali-Mouhim A, Fromentin R, Chamberland A, Jenabian MA, Baril JG, Trottier B, Thomas R, Tremblay CL, Durand M, Chomont N; Canadian HIV and Aging Cohort Study. Turcotte I, et al. Clin Infect Dis. 2023 Apr 3;76(7):1318-1321. doi: 10.1093/cid/ciac874. Clin Infect Dis. 2023. PMID: 36346439 Free PMC article.
Antiretroviral therapy-treated HIV-infected adults with coronary artery disease are characterized by a distinctive regulatory T-cell signature.
Rothan C, Yero A, Shi T, Farnos O, Chartrand-Lefebvre C, El-Far M, Costiniuk CT, Tsoukas C, Tremblay C, Durand M, Jenabian MA; Canadian HIV and Aging Cohort Study. Rothan C, et al. AIDS. 2021 Jun 1;35(7):1003-1014. doi: 10.1097/QAD.0000000000002842. AIDS. 2021. PMID: 33587446
METHODS: Blood specimens were obtained from 142 participants including ART-treated HIV-infected adults with (n = 43) or without CAD (n = 41), as well as HIV-uninfected controls with (n = 31) or without CAD (n = 27). ...
METHODS: Blood specimens were obtained from 142 participants including ART-treated HIV-infected adults with (n = 43) or without CAD ( …
Knowledge of Cannabinoid Content Among People Living with HIV Who Use Cannabis: a Daily Diary Study.
Coelho SG, Rueda S, Costiniuk CT, Jenabian MA, Margolese S, Mandarino E, Shuper PA, Hendershot CS, Cunningham JA, Arbess G, Singer J, Wardell JD. Coelho SG, et al. Int J Behav Med. 2023 Oct 4. doi: 10.1007/s12529-023-10221-x. Online ahead of print. Int J Behav Med. 2023. PMID: 37794278
However, no studies have examined cannabinoid concentration knowledge among PLWH. METHOD: PLWH (N = 29; 76% men, mean age 47 years) reporting cannabis use for both medicinal and nonmedicinal reasons completed daily surveys over 14 days assessing cannabis products used, kno …
However, no studies have examined cannabinoid concentration knowledge among PLWH. METHOD: PLWH (N = 29; 76% men, mean age 47 years) r …
Characterization of people living with HIV in a Montreal-based tertiary care center with COVID-19 during the first wave of the pandemic.
Fehr D, Lebouché B, Ruppenthal L, Brownc M, Obasc N, Bourbonnière E, Girouard J, Massicotte A, Jenabian MA, Almomen AA, Frenette C, de Pokomandy A, Cox J, Giannakis A, Cheng M, Kronfli N, Tsoukas C, Zahedi N, Szabo J, Dehghani K, Brouillette MJ, Falutz J, Turner H, Hamel A, Duchesneau C, Lanthier-Brun J, Klein M, Routy JP, Costiniuk CT. Fehr D, et al. AIDS Care. 2022 May;34(5):663-669. doi: 10.1080/09540121.2021.1904500. Epub 2021 Mar 28. AIDS Care. 2022. PMID: 33779425
Data on demographics, socioeconomic status, co-morbidities and severity of COVID-19 and outcomes were extracted. Of 1702 individuals, 32 (1.9%) had a positive COVID-19 test (n = 24) or symptoms suspicious for COVID-19 (n = 3). Median age was 52 years [IQR 40, 62]. . …
Data on demographics, socioeconomic status, co-morbidities and severity of COVID-19 and outcomes were extracted. Of 1702 individuals, 32 (1. …
Disentangling Medicinal and Recreational cannabis Use Among People Living with HIV: An Ecological Momentary Assessment Study.
Wardell JD, Rueda S, Fox N, Costiniuk CT, Jenabian MA, Margolese S, Mandarino E, Shuper P, Hendershot CS, Cunningham JA, Arbess G, Singer J. Wardell JD, et al. AIDS Behav. 2023 Apr;27(4):1350-1363. doi: 10.1007/s10461-022-03871-7. Epub 2022 Nov 7. AIDS Behav. 2023. PMID: 36342567
This study examined the feasibility of using ecological momentary assessment (EMA) to disentangle medicinal cannabis use (MCU) from recreational cannabis use (RCU) among people living HIV (PLWH). Over a 14-day period, PLWH (N = 29) who engaged in both MCU and RCU completed …
This study examined the feasibility of using ecological momentary assessment (EMA) to disentangle medicinal cannabis use (MCU) from recreati …
A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients.
Nodehi RS, Kalantari B, Raafat J, Ansarinejad N, Moazed V, Mortazavizadeh SMR, Hosseinzadeh M, Ghaderi B, Jenabian A, Qadyani M, Haghighat S, Allahyari A, Mirzania M, Seghatoleslami M, Payandeh M, Alikhasi A, Kafi H, Shahi F. Nodehi RS, et al. BMC Pharmacol Toxicol. 2022 Jul 28;23(1):57. doi: 10.1186/s40360-022-00599-x. BMC Pharmacol Toxicol. 2022. PMID: 35902898 Free PMC article. Clinical Trial.
RESULTS: Ninety-two participants were analyzed in the per-protocol population (TA4415V, n = 48; reference trastuzumab, n = 44). The pCR rates were 37.50% and 34.09% with TA4415V and reference drug, respectively. ...
RESULTS: Ninety-two participants were analyzed in the per-protocol population (TA4415V, n = 48; reference trastuzumab, n = 44) …
26 results